Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05129748

A Multicenter Randomized Phase II Trial of Sodium Thiosulfate and Mannitol to Reduce Hearing Loss in Adults Receiving Cisplatin Chemotherapy

Led by Sunnybrook Health Sciences Centre · Updated on 2023-04-14

92

Participants Needed

1

Research Sites

47 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the effects of sodium thiosulfate and mannitol on preventing hearing loss caused by cisplatin chemotherapy in adult cancer patients. This phase II randomized trial aims to evaluate if these drugs can protect the inner ear cells and reduce ototoxicity, which is a common side effect of cisplatin treatment. The study includes a pilot phase to assess feasibility, safety, and treatment outcomes. Participants are randomly assigned to one of two groups: one receiving standard cisplatin chemotherapy alone, and the other receiving cisplatin chemotherapy followed by intravenous sodium thiosulfate and mannitol 4 to 8 hours later. Mannitol is infused over 30 minutes, then sodium thiosulfate over 15 minutes, as part of post-chemotherapy hydration. The pilot study involves 24 patients over two years, with plans to expand based on initial results. Before treatment, participants undergo hearing tests to establish baseline hearing levels. Follow-up hearing assessments are done at specific intervals after completing cancer therapy to measure changes in hearing thresholds. Researchers will also monitor kidney and liver function, survival outcomes, and report any adverse effects over a 12-month period. The total study duration and ongoing monitoring aim to ensure safety and evaluate the long-term impact of the intervention.

CONDITIONS

Brief Title

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undergoing systemic cisplatin chemotherapy for cancer treatment
  • Age 18 years or older
  • Willing to provide informed consent
  • ECOG performance status between 0 and 2
  • Negative pregnancy test for females of childbearing potential before study treatment
  • Agreement to use effective contraception if of reproductive age during the trial
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Severe to profound sensorineural hearing loss in one or both ears confirmed by audiogram
  • History of Meniere's disease or fluctuating hearing loss
  • Asymmetrical hearing loss based on specific audiogram thresholds
  • Abnormal kidney function with creatinine clearance less than 60 ml/min
  • Abnormal liver function with elevated liver tests beyond specified limits
  • Previous allergic reaction to sodium thiosulfate or mannitol
  • Pregnant or nursing women
  • Inability to follow the study protocol for any reason

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Duration of chemotherapy treatment cycles

Participants receive cisplatin chemotherapy. Those in the experimental group will also receive sodium thiosulfate and mannitol intravenously 4 to 8 hours after chemotherapy as part of post-chemotherapy hydration.

Visits for each chemotherapy cycle including infusion of sodium thiosulfate and mannitol in the experimental group

Follow-up

Duration - Up to 12 months

Participants undergo follow-up hearing tests and monitoring for potential oncological impacts and adverse events after completion of cancer treatment.

Follow-up visits at select time intervals over 12 months

Trial Site Locations

Total: 1 location

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Actively Recruiting

Loading map...

Research Team

Y

Yasmeen Aboulhawa

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Ototoxicity in Patients With a Metal-on-Metal Hip Arthroplas...

Ototoxic Hearing Loss

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here